PL3740222T3 - Zmodyfikowane białko kapsydu raav do terapii genowej - Google Patents

Zmodyfikowane białko kapsydu raav do terapii genowej

Info

Publication number
PL3740222T3
PL3740222T3 PL19701080.4T PL19701080T PL3740222T3 PL 3740222 T3 PL3740222 T3 PL 3740222T3 PL 19701080 T PL19701080 T PL 19701080T PL 3740222 T3 PL3740222 T3 PL 3740222T3
Authority
PL
Poland
Prior art keywords
gene therapy
capsid protein
raav capsid
modified raav
modified
Prior art date
Application number
PL19701080.4T
Other languages
English (en)
Inventor
Jonathan Douglas FINN
Dirk Grimm
Kathleen BÖRNER
Susanne Anna Snoek
Niels Broekstra
Sabine Maria Gertrude Van Der Sanden
Original Assignee
Meiragtx Uk Ii Limited
Universität Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiragtx Uk Ii Limited, Universität Heidelberg filed Critical Meiragtx Uk Ii Limited
Publication of PL3740222T3 publication Critical patent/PL3740222T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL19701080.4T 2018-01-17 2019-01-17 Zmodyfikowane białko kapsydu raav do terapii genowej PL3740222T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18152133 2018-01-17
PCT/EP2019/051128 WO2019141765A1 (en) 2018-01-17 2019-01-17 A modified raav capsid protein for gene therapy

Publications (1)

Publication Number Publication Date
PL3740222T3 true PL3740222T3 (pl) 2023-12-04

Family

ID=61022137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19701080.4T PL3740222T3 (pl) 2018-01-17 2019-01-17 Zmodyfikowane białko kapsydu raav do terapii genowej

Country Status (27)

Country Link
US (1) US12480138B2 (pl)
EP (1) EP3740222B1 (pl)
JP (1) JP7389040B2 (pl)
KR (1) KR102919991B1 (pl)
CN (1) CN112004544B (pl)
AU (1) AU2019209595B2 (pl)
BR (1) BR112020014625A2 (pl)
CA (1) CA3087910C (pl)
DK (1) DK3740222T5 (pl)
EA (1) EA202091712A1 (pl)
ES (1) ES2957622T3 (pl)
FI (1) FI3740222T3 (pl)
HR (1) HRP20231126T1 (pl)
HU (1) HUE062774T2 (pl)
IL (1) IL275838B2 (pl)
LT (1) LT3740222T (pl)
MX (1) MX2020006764A (pl)
MY (1) MY202252A (pl)
PH (1) PH12020551096A1 (pl)
PL (1) PL3740222T3 (pl)
PT (1) PT3740222T (pl)
RS (1) RS64499B1 (pl)
SG (1) SG11202006056RA (pl)
SI (1) SI3740222T1 (pl)
SM (1) SMT202300284T1 (pl)
WO (1) WO2019141765A1 (pl)
ZA (1) ZA202004980B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
JP2020530307A (ja) * 2017-06-30 2020-10-22 インティマ・バイオサイエンス,インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
RS64499B1 (sr) 2018-01-17 2023-09-29 Meiragtx Uk Ii Ltd Modifikovani protein kapsida raav za gensku terapiju
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
WO2019195423A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
WO2019195444A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
CN110437317B (zh) * 2019-01-30 2023-05-02 上海科技大学 具有变异衣壳蛋白的腺相关病毒及其用途
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
KR20220081971A (ko) * 2019-07-15 2022-06-16 메이라지티엑스 유케이 Ii 리미티드 관절염 질환 치료용 변형된 aav 캡시드 단백질
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
KR20220083708A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 Aav 전달 카세트
CN110950934B (zh) * 2019-12-31 2022-11-04 复旦大学 一种腺相关病毒衣壳蛋白、载体及其构建方法与应用
EP4110792A4 (en) * 2020-02-25 2024-08-21 Children's Medical Research Institute POLYPEPTIDES AND CAPSIDIC VECTORS OF ADENO-ASSOCIATED VIRUSES
MX2023002016A (es) 2020-08-19 2023-06-26 Sarepta Therapeutics Inc Vectores de virus adenoasociados para el tratamiento del sindrome de rett.
GB202110014D0 (en) * 2021-07-12 2021-08-25 Cytiva Bioprocess R & D Ab A method for separating adeno-associated virus capsids, compositions obtained by said method and uses thereof
EP4413147A4 (en) 2021-10-08 2025-07-30 Dyno Therapeutics Inc CAPSID VARIANTS AND METHODS OF USE THEREOF
WO2024191778A1 (en) 2023-03-10 2024-09-19 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2024213660A1 (en) 2023-04-13 2024-10-17 Meiragtx Uk Ii Limited Inflammation-inducible promoters
CN119320802A (zh) * 2023-07-17 2025-01-17 苏州吉恒基因科技有限公司 单链单极DNA重组腺相关病毒的cis包装元件、spAAV载体和应用
AU2024332181A1 (en) 2023-08-31 2026-02-12 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
AU2002360355B2 (en) 2001-11-09 2005-07-07 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US8529885B2 (en) * 2003-09-01 2013-09-10 Academisch Medisch Centrum AAV vectors for in vivo gene therapy of rheumatoid arthritis
DK1664315T3 (da) * 2003-09-01 2012-07-09 Amc Amsterdam AAV-vektorer til in vivo genterapi af rheumatoid arthritis
AU2010201278B2 (en) * 2003-09-01 2012-11-15 Academisch Medisch Centrum AAV vectors for in vivo gene therapy of rheumatoid arthritis
AU2006304997B2 (en) 2005-10-20 2012-03-01 Uniqure Ip B.V. Improved AAV vectors produced in insect cells
WO2007120542A2 (en) * 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
ES2785223T3 (es) 2006-06-21 2020-10-06 Uniqure Ip Bv Células de insecto para la producción de vectores de AAV
EP2061891B1 (en) 2006-08-24 2012-04-11 Virovek, Inc. Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
SI2173888T1 (sl) 2007-07-26 2017-01-31 Uniqure Ip B.V. Bakulovirusni vektorji, ki vsebujejo ponavljajoča kodirna zaporedja z različnimi kodonskimi preferencami
ES2644880T3 (es) 2008-02-19 2017-11-30 Uniqure Ip B.V. Optimización de expresión de proteínas Rep y Cap parvovirales en las células de insecto
EP2297185A1 (en) 2008-06-17 2011-03-23 Amsterdam Molecular Therapeutics (AMT) B.V. Parvoviral capsid with incorporated gly-ala repeat region
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
AU2012304993B2 (en) 2011-09-08 2017-09-14 Uniqure Ip B.V. Removal of contaminating viruses from AAV preparations
WO2013174760A1 (en) * 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Optimized aav-vectors for high transduction rates in dendritic cells
KR102298579B1 (ko) * 2013-05-21 2021-09-07 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도
DE102014207498A1 (de) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
CN104107438A (zh) * 2014-05-29 2014-10-22 中国人民解放军军事医学科学院基础医学研究所 Spry2在制备预防和治疗类风湿性关节炎药物中的应用
WO2016055437A1 (en) 2014-10-06 2016-04-14 Arthrogen B.V. Aav-based gene therapy
US10876134B2 (en) * 2014-12-16 2020-12-29 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
DK3402530T3 (da) 2016-01-13 2020-11-23 Genzyme Corp Rekombinante aav-vektorer, der udtrykker knoglebeskyttende gener, herunder has2 og lubricin, som er anvendelige til behandling af osteoarthritis og relaterede ledtilstande hos pattedyr
US11207382B2 (en) 2016-08-19 2021-12-28 University Of Florida Research Foundation, Incorporated Compositions for treating conditions using recombinant self-complementary adeno-associated virus
KR20250121159A (ko) 2016-12-07 2025-08-11 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 인터류킨-1 수용체 길항제(IL-1RA) cDNA
WO2018189244A1 (en) 2017-04-11 2018-10-18 Ruprecht-Karls-Universität Heidelberg Adeno-associated virus library
KR102612563B1 (ko) * 2017-08-31 2023-12-11 베니텍 아이피 홀딩스 아이엔씨. 변형된 포스포리파제 도메인을 갖는 아데노-연관 바이러스 (aav)
RS64499B1 (sr) 2018-01-17 2023-09-29 Meiragtx Uk Ii Ltd Modifikovani protein kapsida raav za gensku terapiju
KR20220081971A (ko) * 2019-07-15 2022-06-16 메이라지티엑스 유케이 Ii 리미티드 관절염 질환 치료용 변형된 aav 캡시드 단백질

Also Published As

Publication number Publication date
IL275838A (en) 2020-08-31
JP2021510528A (ja) 2021-04-30
HRP20231126T1 (hr) 2024-01-05
EP3740222A1 (en) 2020-11-25
PH12020551096A1 (en) 2021-06-21
AU2019209595A1 (en) 2020-09-03
SG11202006056RA (en) 2020-07-29
WO2019141765A1 (en) 2019-07-25
ZA202004980B (en) 2025-07-30
ES2957622T3 (es) 2024-01-23
FI3740222T3 (fi) 2023-07-26
EA202091712A1 (ru) 2021-02-16
PT3740222T (pt) 2023-07-11
EP3740222B1 (en) 2023-06-28
KR102919991B1 (ko) 2026-01-29
CA3087910C (en) 2025-04-08
DK3740222T5 (da) 2024-08-26
CN112004544B (zh) 2024-08-06
CA3087910A1 (en) 2019-07-25
CN112004544A (zh) 2020-11-27
US20200354744A1 (en) 2020-11-12
IL275838B1 (en) 2024-07-01
MX2020006764A (es) 2021-01-08
RS64499B1 (sr) 2023-09-29
IL275838B2 (en) 2024-11-01
DK3740222T3 (da) 2023-07-31
SMT202300284T1 (it) 2023-11-13
NZ767106A (en) 2023-10-27
US12480138B2 (en) 2025-11-25
HUE062774T2 (hu) 2023-12-28
BR112020014625A2 (pt) 2020-12-08
KR20200135768A (ko) 2020-12-03
SI3740222T1 (sl) 2023-11-30
LT3740222T (lt) 2023-09-11
MY202252A (en) 2024-04-19
JP7389040B2 (ja) 2023-11-29
AU2019209595B2 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
HUE062774T2 (hu) Módosított rAAV kapszidfehérje génterápiához
EP3645021A4 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EP3856913A4 (en) Adeno-associated virus compositions for targeted gene therapy
EP4041755A4 (en) Modified aav capsids and uses thereof
IL263801A (en) Novel adeno-associated virus capsid proteins
IL286825A (en) Gene therapy for eye pathologies
DK3390429T3 (da) Modificerede kapsid-proteiner til forbedret afgivelse af parvovirus-vektorer
IL270567B (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
EP3575398A4 (en) ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
EP3526333A4 (en) AAV CAPSIDE DESIGNS
IL282411A (en) Methods for analysis of viral capsid protein composition
SI3471780T1 (sl) Zdravljenje SDM-ja z uporabo različice AAV2 z afliberceptom
EP4019642A4 (en) Isolated modified vp1 capsid protein of aav5
PL3612624T3 (pl) Terapia genowa
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
IL289826A (en) Modified aav capsid proteins for the treatment of arthritis
IL292625A (en) Viruses with modified capsid proteins
EP3484520A4 (en) STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS
EP3717652A4 (en) GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IIIB
EP4051324A4 (en) Gene therapy vectors
SG11202009854XA (en) Modified viral capsids
PL3740199T3 (pl) Enkapsułkowane polimerem wektory wirusowe do terapii genetycznej
SI3612237T1 (sl) Genska terapija
DK3737402T5 (da) Modificeret protein
MA52180A (fr) Vaccins thérapeutiques anti-abêta